Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of the Activity and Safety of Lenalidomide and Rituximab as Non-chemotherapy Therapy for Patients With Recurrent and Refractory Chronic Lymphocytic Leukemia

NCT01185262 is registered in ClinicalTrials.gov with MD Anderson International Spain SA as lead sponsor.

NCT NCT01185262
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01185262 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of the Activity and Safety of Lenalidomide and Rituximab as Non-chemotherapy Therapy for Patients With Recurrent and Refractory Chronic Lymphocytic Leukemia
Lead sponsor
MD Anderson International Spain SA
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2009
Completion date
September 30, 2013
Enrollment
25 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia